Retatrutide grey-market supply — claim review
Retatrutide is Eli Lilly's investigational triple GLP-1 / GIP / glucagon agonist. Phase 2 data showed ~24% weight loss; Phase 3 (TRIUMPH) is ongoing. It is not licensed anywhere. Yet 'retatrutide' is widely sold by grey-market vendors. This page explains the regulatory and identity situation honestly — without telling you how to obtain it.
What grey-market sellers claim
- “Pre-launch access to the next-generation Mounjaro”
- “Pharmaceutical-grade retatrutide for research use”
- “24% weight loss guaranteed at 48 weeks”
- “Cheaper than waiting for the licensed version”
The honest situation
Retatrutide is not a UK medicine. No retailer, online clinic, or 'compounding pharmacy' anywhere in the world is licensed to supply it for human use. Vials sold as 'retatrutide' cannot be verified — there is no licensed reference product to compare against.
Phase 2 trial data are genuinely promising (the headline weight-loss figures are real). Phase 3 outcome data and safety surveillance are not yet complete. Long-term effects of sustained glucagon-receptor agonism in humans are not characterised.
UK regulatory framing
Supply for human use is unlawful under the Human Medicines Regulations 2012 for any unlicensed medicine. Advertising retatrutide for human-use indications engages further offences. The MHRA has issued statements on unlawful weight-loss supply generally; see our counterfeit medicine timeline.
The lawful route
- Enrolment in a registered TRIUMPH-programme Phase 3 trial via ClinicalTrials.gov.
- Licensed Wegovy (semaglutide) via NHS or GMC-registered prescriber for clinically appropriate cases.
- Licensed Mounjaro (tirzepatide) via NHS specialist (NICE TA1026) or registered private clinic.
Frequently asked questions
- Is retatrutide available for UK private prescription?
- No. Retatrutide is not licensed anywhere in the world at the time of writing. Any UK seller offering it is operating outside the regulated supply chain and the product identity is unverified.
- Will retatrutide be approved soon?
- Eli Lilly's TRIUMPH Phase 3 programme is ongoing. Regulatory submission may follow but is not guaranteed. Lawful access today is via enrolment in a registered Phase 3 trial, not via grey-market vendors.
- Is grey-market 'retatrutide' actually retatrutide?
- There is no way for a consumer or a clinician to verify this. Products sold as retatrutide may contain a different GLP-1 (relabelled semaglutide / tirzepatide), nothing, or a contaminated compound. Identity testing is not part of grey-market supply.
- What are the safety risks of grey-market retatrutide?
- Unverified identity, unverified concentration, unverified sterility, no clinical supervision for an investigational compound. The licensed reference product does not exist, so there is no Patient Information Leaflet, no MHRA Drug Safety Update history, no marketing-authorisation conditions.
- What should I do if I want access to retatrutide?
- Search ClinicalTrials.gov for TRIUMPH-programme studies in your area. Discuss with your GP. For weight management, the licensed UK options are Wegovy (semaglutide) and Mounjaro (tirzepatide) via NHS or GMC-registered private prescriber.